Malaria Drug Resistance and Disease Virulence

疟疾耐药性和疾病毒力

• 批准号: 8745299
• 负责人: Thomas E Wellems
• 金额: $ 134.93万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8745299
• 关键词: Africa; Antimalarials; Area; Asia; Cessation of life; Development; Diagnostic; Diagnostic tests; Disease; Drug resistance; Genes; Human; Infection; Investigation; Knowledge; Laboratories; Malaria; Modeling; Parasites; Plasmodium falciparum; Plasmodium vivax; Primates; Process; Research; Research Activity; Research Project Grants; Resistance; South America; Testing; Vaccines; Virulence; chemotherapy; disability; drug candidate; field study; improved; multidisciplinary; novel diagnostics; novel therapeutic intervention; programs; response; tool; vaccine candidate

Our research project focuses on how malaria parasites become resistant to major antimalarial drugs and why strains of the two species responsible most human malaria disability and death (Plasmodium falciparum and Plasmodium vivax) show different infectivities to humans and other primates. In these areas of research, we seek advances that can improve the knowledge of disease processes in malaria and thereby support the development or testing of new antimalarial chemotherapies, diagnostic tools, and vaccines. The research activities in our program are multidisciplinary and include field studies in malarious regions of Africa, Asia and South America, as well as programs of basic laboratory investigation.

我们的研究项目重点关注疟疾寄生虫如何对主要抗疟药物产生抗药性，以及为什么导致大多数人类疟疾致残和死亡的两个物种菌株（恶性疟原虫和间日疟原虫）对人类和其他灵长类动物表现出不同的感染性。在这些研究领域，我们寻求能够提高对疟疾疾病过程的了解的进展，从而支持新的抗疟化疗、诊断工具和疫苗的开发或测试。我们项目的研究活动是多学科的，包括在非洲、亚洲和南美洲的疟疾地区进行实地研究，以及基础实验室调查项目。